Motley Fool Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Motley Fool Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.1M	Sell	42,836 -16,701	-28%	-$7.79M	2.16%	8
2025 Q4	$27M	Sell	59,537 -11,812	-17%	-$5.09M	2.09%	10
2025 Q3	$27.9M	Buy	71,349 +17,436	+32%	+$7.29M	1.89%	10
2025 Q2	$24M	Buy	53,913 +20,864	+63%	+$9.61M	1.45%	19
2025 Q1	$16M	Sell	33,049 -3,412	-9%	-$1.59M	0.95%	28
2024 Q4	$14.7M	Sell	36,461 -3,032	-8%	-$1.41M	0.76%	40
2024 Q3	$18.4M	Sell	39,493 -1,747	-4%	-$839K	0.92%	32
2024 Q2	$19.4M	Sell	41,240 -834	-2%	-$362K	0.99%	29
2024 Q1	$17.6M	Buy	+42,074	New	+$17.8M	0.91%	33

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Motley Fool Wealth Management's VRTX Position: Q1 2026 in Review

Motley Fool Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 28% in Q1 2026, selling an estimated $7.79M and leaving 42,836 shares worth $19.1M. The position accounts for 2.16% of the portfolio, ranked #8.

Motley Fool Wealth Management first reported a position in VRTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $27.9M in Q3 2025. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Motley Fool Wealth Management held 42,836 shares of Vertex Pharmaceuticals worth $19.1M as of Q1 2026.
Motley Fool Wealth Management sold 16,701 Vertex Pharmaceuticals shares in Q1 2026, an estimated $7.79M.
Vertex Pharmaceuticals made up 2.16% of Motley Fool Wealth Management's portfolio in Q1 2026, its #8 holding.
Motley Fool Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Motley Fool Wealth Management's Vertex Pharmaceuticals position peaked at $27.9M in Q3 2025.
1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Motley Fool Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.